Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2023

Open Access 02-05-2023 | Lymphoma | Case report

Primary hepatic Epstein–Barr virus-positive diffuse large B-cell lymphoma associated with azathioprine immunosuppression: a case report

Authors: Paulina S. Marell, Min Shi, Majken T. Wingo

Published in: Journal of Medical Case Reports | Issue 1/2023

Login to get access

Abstract

Background

Hepatic masses are relatively common findings, and the diagnostic approach often begins by identifying patient and mass characteristics that are risk factors for malignancy. Chronic immunosuppression is a known risk factor for various malignancies, and azathioprine in particular has been reported in association with solid and hematologic malignancies, including diffuse large B-cell lymphoma.

Case presentation

A 46-year-old white woman presented to clinic with several weeks of gastrointestinal symptoms and was found to have a hepatic mass on imaging. Her history was notable for neuromyelitis optica spectrum disorder on chronic immunosuppression with azathioprine. It was initially thought to be an inflammatory adenoma. On 6-month follow-up imaging, the mass had grown rapidly in size and was surgically resected. Further workup determined the mass to be an iatrogenic immunodeficiency-associated Epstein–Barr virus-positive diffuse large B-cell lymphoma confined to the liver. Azathioprine was discontinued and the patient underwent treatment with rituximab with no evidence of recurrence 2 years after the initiation of treatment.

Conclusions

This case report describes the first time hepatic Epstein–Barr virus-positive diffuse large B-cell lymphoma has been reported with azathioprine, which highlights the unique sequelae of chronic immunosuppression, including atypical hematologic malignancies, and the importance of considering chronic immunosuppression in the diagnostic evaluation of a hepatic mass.
Literature
1.
go back to reference Cartwright SL, Knudson MP. Diagnostic imaging of acute abdominal pain in adults. Am Fam Physician. 2015;91(7):452–9.PubMed Cartwright SL, Knudson MP. Diagnostic imaging of acute abdominal pain in adults. Am Fam Physician. 2015;91(7):452–9.PubMed
9.
go back to reference Kinlen L. Immunosuppressive therapy and acquired immunological disorders. Cancer Res. 1992;52(19 Suppl):5474s–6s.PubMed Kinlen L. Immunosuppressive therapy and acquired immunological disorders. Cancer Res. 1992;52(19 Suppl):5474s–6s.PubMed
10.
go back to reference Azathioprine. In: In-Depth Answers [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 Sept 14]. Available from: www.micromedexsolutions.com. Subscription required to view. Azathioprine. In: In-Depth Answers [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 Sept 14]. Available from: www.​micromedexsoluti​ons.​com. Subscription required to view.
11.
go back to reference Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46:1607–12.CrossRefPubMed Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46:1607–12.CrossRefPubMed
12.
go back to reference Arnold JA, Ranson SA, Abdalla SH. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin Lab Haem. 1999;21:289–92.CrossRef Arnold JA, Ranson SA, Abdalla SH. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin Lab Haem. 1999;21:289–92.CrossRef
13.
go back to reference Au WY, Yuen MF, Lai KC, et al. Clonal marrow abnormalities after azathioprine and sulfasalazine exposure in Crohn’s disease: a cautionary tale. Leuk Lymphoma. 2002;43(8):1679–81.CrossRefPubMed Au WY, Yuen MF, Lai KC, et al. Clonal marrow abnormalities after azathioprine and sulfasalazine exposure in Crohn’s disease: a cautionary tale. Leuk Lymphoma. 2002;43(8):1679–81.CrossRefPubMed
14.
go back to reference Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104(3):822–8.CrossRefPubMed Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104(3):822–8.CrossRefPubMed
16.
go back to reference Aguilar HI, Burgart LJ, Geller A, et al. Azathioprine-induced lymphoma manifesting as fulminant hepatic failure. Mayo Clin Proc. 1997;72:643–5.CrossRefPubMed Aguilar HI, Burgart LJ, Geller A, et al. Azathioprine-induced lymphoma manifesting as fulminant hepatic failure. Mayo Clin Proc. 1997;72:643–5.CrossRefPubMed
17.
18.
go back to reference US Food and Drug Administration: FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T-Cell Lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine. US Food and Drug Administration. Silver Spring, MD. 2011. Available from URL: http://www.fda.go. As accessed 2011–04–14. US Food and Drug Administration: FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T-Cell Lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine. US Food and Drug Administration. Silver Spring, MD. 2011. Available from URL: http://​www.​fda.​go. As accessed 2011–04–14.
19.
go back to reference Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25. https://doi.org/10.1016/S0140-6736(09)61302-7.CrossRefPubMed Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25. https://​doi.​org/​10.​1016/​S0140-6736(09)61302-7.CrossRefPubMed
35.
go back to reference Zelenetz AD, Gordon LI, Abramson JS, et al. B-cell Lymphomas. Version 4.2021. In: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology- B-Cell Lymphomas. NCCN 2021 May from NCCN.org/guidelines Zelenetz AD, Gordon LI, Abramson JS, et al. B-cell Lymphomas. Version 4.2021. In: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology- B-Cell Lymphomas. NCCN 2021 May from NCCN.org/guidelines
37.
go back to reference Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2.CrossRefPubMedPubMedCentral Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. https://​doi.​org/​10.​1038/​s41375-022-01620-2.CrossRefPubMedPubMedCentral
Metadata
Title
Primary hepatic Epstein–Barr virus-positive diffuse large B-cell lymphoma associated with azathioprine immunosuppression: a case report
Authors
Paulina S. Marell
Min Shi
Majken T. Wingo
Publication date
02-05-2023

Other articles of this Issue 1/2023

Journal of Medical Case Reports 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine